Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4

3 hours ago 2

Soumya Eswaran

Mon, January 12, 2026 astatine 8:05 AM CST 2 min read

ClearBridge Investments, an concern absorption company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. US equities reported a beardown but volatile show successful the 4th quarter, with the S&P 500 Index returning 2.7% portion the benchmark Russell Midcap Growth Index declined 3.7%. In this environment, a balanced, highly progressive stock attack resulted successful Strategy’s 3rd consecutive 4th of outperformance, capturing aboriginal momentum portion providing downside extortion during rising volatility towards the extremity of the period. The strategy maintained its semipermanent concern doctrine of disciplined portfolio absorption and opportunistic superior allocation. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, ClearBridge Growth Strategy highlighted stocks specified arsenic Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is simply a biotechnology institution focusing connected processing and commercializing therapies for treating cystic fibrosis (CF). The one-month instrumentality of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 1.79%, and its shares gained 12.21% of their worth implicit the past 52 weeks. On January 9, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) banal closed astatine $463.86 per share, with a marketplace capitalization of $118.929 billion.

ClearBridge Growth Strategy stated the pursuing regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) successful its 4th fourth 2025 capitalist letter:

"Positive contributions from steadier maturation holdings helped to offset these pressures. Within wellness care, apical idiosyncratic contributor Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) benefited from increasing optimism astir its kidney illness pipeline and continued to show the worth of idiosyncratic, innovation driven growth."

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge money portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) astatine the extremity of the 3rd quarter, which was 53 successful the erstwhile quarter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) delivered $3.08 cardinal in revenue in the 3rd quarter, representing a 11% maturation compared to Q3 2024. While we admit the imaginable of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.